Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Клинический случай наблюдения пациента с ожирением и неалкогольной жировой болезнью печени
Клинический случай наблюдения пациента с ожирением и неалкогольной жировой болезнью печени
К.А.Комшилова, Е.А.Трошина. Клинический
случай наблюдения пациента с ожирением и неалкогольной жировой болезнью печени.
Справочник поликлинического врача. 2015;
6-8: 36–38.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Targher G et al. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl J Med 2010.
2. Misra VL, Khashab M, Chalasani N. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009; 11: 50–5.
3. Stefan N, Kantartzis K, Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews 2008; 29 (7): 939–60.
4. Lazo M, Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28 (4): 339–50.
5. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews 2010; 11 (6): 430–45.
6. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103 (2): 71–83.
7. Festi D, Colecchia A, Sacco T et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5 (1): 27–42.
8. Adams L, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgraduate medical J 2006; 82: 315–22.
9. Marchesini G, Bianchi G, Tomassetti S et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358 (9285): 893–4.
10. Nair S, Diehl A, Wiseman M. Metformin in the triement of non- alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23–8.
11. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–85.
12. Chalasani N, Younossi Z, Lavine JE et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012;107: 811–26.
13. Kleiner DE, Brunt EM, Van Natta M et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6): 1313–21.
2. Misra VL, Khashab M, Chalasani N. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009; 11: 50–5.
3. Stefan N, Kantartzis K, Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews 2008; 29 (7): 939–60.
4. Lazo M, Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28 (4): 339–50.
5. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews 2010; 11 (6): 430–45.
6. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103 (2): 71–83.
7. Festi D, Colecchia A, Sacco T et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5 (1): 27–42.
8. Adams L, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgraduate medical J 2006; 82: 315–22.
9. Marchesini G, Bianchi G, Tomassetti S et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358 (9285): 893–4.
10. Nair S, Diehl A, Wiseman M. Metformin in the triement of non- alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23–8.
11. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–85.
12. Chalasani N, Younossi Z, Lavine JE et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012;107: 811–26.
13. Kleiner DE, Brunt EM, Van Natta M et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6): 1313–21.
Авторы
К.А.Комшилова, Е.А.Трошина
ФГБУ Эндокринологический научный центр Минздрава России
ФГБУ Эндокринологический научный центр Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.